Annamaria Bianco

Dr. Annamaria Bianco

CREA - Research and Clinical Center, Fondazione San Sebastiano of Misericordia di Firenze, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022
Verified
Book Chapter
Closed access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
MAMuhammad Waqar Azeem
Muhammad Waqar Azeem
LULisa Underwood
Lisa Underwood
MSMaria Luisa Scattoni
Maria Luisa Scattoni
APAntonio M. Persico
Antonio M. Persico
KMKerim M Munir
Kerim M Munir

8 June 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
UDUMBERTO DIANZANI
UMBERTO DIANZANI
TCTatiana Costa
Tatiana Costa
DIDaniele Imperiale
Daniele Imperiale
ABAnnamaria Bianco
Annamaria Bianco
ERElisa Rondini
Elisa Rondini
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
Background: Stereotypic behaviour can be defined as a clear behavioural pattern where a specific function or target cannot be identified, although it delays on time. Nonetheless, repetitive and stereotypical behaviours play a key role in both animal and human behaviour. Similar behaviours are observed across species, in typical human developmental phases, and in some neuropsychiatric conditions, such as Autism Spectrum Disorder (ASD) and Intellectual Disability. This evidence led to the spread of animal models of repetitive behaviours to better understand the neurobiological mechanisms underlying these dysfunctional behaviours and to gain better insight into their role and origin within ASD and other disorders. This, in turn, could lead to new treatments of those disorders in humans. Method: This paper maps the literature on repetitive behaviours in animal models of ASD, in order to improve understanding of stereotypies in persons with ASD in terms of characterization, pathophysiology, genomic and anatomical factors. Results: Literature mapping confirmed that phylogenic approach and animal models may help to improve understanding and differentiation of stereotypies in ASD. Some repetitive behaviours appear to be interconnected and mediated by common genomic and anatomical factors across species, mainly by alterations of basal ganglia circuitry. A new distinction between stereotypies and autotypies should be considered. Conclusions: Phylogenic approach and studies on animal models may support clinical issues related to stereotypies in persons with ASD and provide new insights in classification, pathogenesis, and management.

9 May 2025
Verified
Book Chapter
Closed access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
ABAnnamaria Bianco
Annamaria Bianco
VBVeronica Boniotti
Veronica Boniotti
ECEddie Chaplin
Eddie Chaplin

12 May 2022
Verified
Book Chapter
Closed access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
JHJudith Hollenweger Haskell
Judith Hollenweger Haskell
Marc J. TasséMarc J. Tassé
Marc J. Tassé
CSClaudio Straccia
Claudio Straccia
ERElisa Rondini
Elisa Rondini
LSLuis Salvador-Carulla
Luis Salvador-Carulla

12 May 2022
Verified
Book Chapter
Closed access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
RFRobert Fletcher
Robert Fletcher
GWGermain Weber
Germain Weber
CSCarlo Schuengel
Carlo Schuengel
DSDaniela Scuticchio
Daniela Scuticchio
KCKen Courtenay
Ken Courtenay

18 March 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
ABAnnamaria Bianco
Annamaria Bianco
MMMicaela Piva Merli
Micaela Piva Merli
MVMaria Stella Vescio
Maria Stella Vescio
MRMichele Rossi
Michele Rossi
EBElisabetta F. Buonaguro
Elisabetta F. Buonaguro
Background/Objectives: First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are frequently prescribed for the management of problem behaviours (PBs) in people with intellectual developmental disorders (IDDs) with or without autism spectrum disorder (ASD). However, the different effectiveness of these two groups of drugs has not been adequately investigated, especially in terms of person-centred outcomes, such as quality of life (QoL). The aim of the present observational study was to compare the personal QoL of two groups of people with IDDs with and without ASD, attending the same residential facility, but receiving FGAs and SGAs, respectively, for the management of PBs. Methods: Twenty-two people with IDDs (ten with ASD) receiving FGAs and twenty-three (eleven with ASD) receiving SGAs for the management of PBs were consecutively recruited. The participants underwent a complex clinical and instrumental evaluation, including the systematic psychopathological assessment for persons with intellectual and developmental disabilities—general screening (SPAIDD-G), the Wing’s handicaps, behaviours, and skills schedule (HBS), the DOTES, and the BASIQ (QoL Assessment tool battery). Follow-up evaluations were carried out after 6, 12, and 18 months. Results: The use of antipsychotics was withdrawn only in 16 cases, of which only 4 were for significant improvement. Treatment with FGAs was associated with more frequent discontinuation, a higher incidence of side effects, and a trend toward a lower efficacy on PBs than treatment with SGAs. FGAs also improved generic QoL significantly less than SGAs. Conclusions: The present pilot study is the first to compare FGAs and SGAs with respect to the generic QoL in people with IDDs and PBs. SGAs resulted to have a significantly greater positive impact on QoL than FGAs, despite demonstrating similar efficacy in treating PBs.